[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
Article
August 1969

Production and Testing of Rubella Virus Vaccine: Prepared on WI-38 Cell Cultures

Author Affiliations

Philadelphia
From the Research and Development Department, Wyeth Laboratories, Philadelphia.

Am J Dis Child. 1969;118(2):367-371. doi:10.1001/archpedi.1969.02100040369036
Abstract

THE PRESENT availability of several effective experimental, live rubella virus vaccines attests to the comparative ease of attenuating this virus by passaging in tissue culture systems.1 Although the nature of the substrate may have influenced the individual rates of attenuation; nevertheless, a variety of cell systems and combinations have been used successfully for vaccine development, including monkey,2 dog,3 and rabbit4 renal cells, duck-embryo cells,5 and human diploid cells.6 With the exception of the last candidate system utilizing the WI-38 human diploid cell strain, the other experimental preparations have in common been isolated and propagated in "primary" cultures. These are generally mixed populations of cells, freshly explanted from animal tissues and cultivated briefly without deliberate subcultivation. Diploid cells on the other hand during a finite period of viability are serially propagated in a technology which characterizes and standardizes them as acceptable in advance of their

×